The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
February 17, 2025
View Complete Issue         Table of Contents 2019 
Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)
February 17, 2025 (Issue: 1722)
Cosibelimab (Unloxcyt – Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, has been approved by the FDA for treatment of locally advanced or metastatic cutaneous squamous cell carcinoma in adults who are not...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)
Article code: 1722g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.